

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**天津发展控股有限公司**  
**TIANJIN DEVELOPMENT HOLDINGS LIMITED**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 882)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made by Tianjin Development Holdings Limited (the “**Company**”) pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生製藥股份有限公司) (“**Lisheng Pharmaceutical**”), an indirect non-wholly owned subsidiary of the Company, has published an announcement on the website of Shenzhen Stock Exchange ([www.szse.cn](http://www.szse.cn)) in respect of its indicative results for the year of 2025, full text of which is reproduced in the attachment of this announcement.

As at the date of this announcement, the Company indirectly holds approximately 34.11% of the issued share capital of Lisheng Pharmaceutical.

By Order of the Board  
**Tianjin Development Holdings Limited**  
**Teng Fei**  
*Chairman and Executive Director*

Hong Kong, 23 January 2026

*As at the date of this announcement, the Board of the Company consists of Mr. Teng Fei, Dr. Zhai Xinxiang, Mr. Xia Binhui, Mr. Sun Lijun\*, Ms. Ng Yi Kum, Estella\*\*, Mr. Wong Shiu Hoi, Peter\*\*, Mr. Lau Ka Keung\*\* and Mr. Sin Hendrick\*\*.*

\* *non-executive director*

\*\* *independent non-executive director*

## **TIANJIN LISHENG PHARMACEUTICAL CO., LTD.**

### **INDICATIVE RESULTS ANNOUNCEMENT FOR THE YEAR 2025**

The Company and all the members of the Board warrant the truthfulness, accuracy and completeness of the disclosure of such information, and there are no false statements, misleading statements nor material omissions.

#### **I. INDICATIVE RESULTS FOR THE PERIOD**

1. Period for the indicative results: 1 January 2025 to 31 December 2025
2. Indicative results:  Increase over the corresponding period last year
3. Details of the indicative results

Item	Current reporting period	Corresponding period last year
Net profit attributable to the shareholders of the Company	Net profit: RMB 40000 to RMB 44000 (in ten thousand yuan) Increased by approximately 116.77% to 138.44% as compared to the corresponding period last year	Net profit: RMB 18453 (in ten thousand yuan)
Net profit after deducting the extraordinary gains or losses	Net profit: RMB 16000 to RMB 19000 (in ten thousand yuan) Increased by approximately 55.34% to 84.47% as compared to the corresponding period last year	Net profit: RMB 10300 (in ten thousand yuan)
Basic earnings per share	Earnings: RMB 1.50 per share to RMB 1.80 per share	Earnings: RMB 0.72 per share

#### **II. COMMUNICATION WITH THE CERTIFIED PUBLIC ACCOUNTANTS**

The relevant data related to the indicative results is based on the preliminary calculation made by the finance department of the Company and has not been audited by the certified public accountants. Regarding to the relevant matters related to the indicative results over the current reporting period, the Company has communicated with the certified public accountants for annual audit and there is no disagreement among us.

#### **III. EXPLANATION FOR CHANGES IN RESULTS**

During the reporting period, net profit attributable to the shareholders of the Company rose significantly year-on-year, reflecting both improved product sales from intensified market expansion efforts and dividend contributions from Tasly Bio-Medicine Industry Group Co., Ltd.

#### **IV. OTHER RELEVANT INFORMATION**

The data set out in the indicative results is based on the preliminary estimation by the finance department of the Company. The specific results data in details should be those disclosed in the Company's 2025 Annual Report. Investors are advised to exercise caution and pay attention to the investment risks involved.

The Board of Directors of  
Tianjin Lisheng Pharmaceutical Co., Ltd.

24 January 2026